The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector ...
TUCKER, Ga. & ROCKVILLE, Md.--(BUSINESS WIRE)--Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract ...
Results from the Children’s Oncology Group (COG) AML trials showed that benefit from GO at a single dose of 3 mg/m 2 at first induction and then intensification 9 was restricted to paediatric patients ...
The Annals of Applied Statistics, Vol. 7, No. 2 (June 2013), pp. 799-822 (24 pages) Sparse latent multi-factor models have been used in many exploratory and predictive problems with high-dimensional ...
Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers Expression of M-CSF and density of ...
Conclusion: Expression of the cell adhesion molecule CEACAM6 in CRC is an independent prognostic factor allowing subdivision of patients into low- and high-risk groups. Whether CEACAM6 or CEA and ...
Plant steroid hormones, brassinosteroids (BRs), regulate essential growth and developmental processes. BRs signal through membranelocalized receptor BRI1 and several other signaling components to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results